Intelligent Bio Solutions Closes $10 Million Private Placement with Institutional Investors
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 02 2026
0mins
Source: Globenewswire
- Successful Financing: Intelligent Bio Solutions Inc. has completed a private placement with two healthcare-focused institutional investors, issuing 2,298,850 shares of common stock and associated warrants, expected to generate approximately $10 million in gross proceeds, thereby enhancing the company's liquidity for future growth.
- Clear Use of Proceeds: The funds raised will be allocated for working capital and general corporate purposes, including financing the 510(k) submission for FDA approval of its non-invasive Intelligent Fingerprinting Drug Screening System, indicating strong confidence in the product's market potential.
- Market Expansion Plans: The company intends to leverage the proceeds to further expand into international markets, particularly in sectors such as construction, manufacturing, and transport, showcasing its strategic positioning in safety-critical industries.
- Compliance Commitment: INBS has committed to filing a registration statement with the SEC within 10 days of the agreement to facilitate the resale of shares by investors, thereby enhancing investor confidence and ensuring compliance with securities laws.
Analyst Views on INBS
About INBS
Intelligent Bio Solutions Inc. is a medical technology company focused on developing and delivering intelligent, rapid, non-invasive testing and screening solutions. Its segment includes Commercially available Intelligent Fingerprinting Products and Development Stage Biosensor Platform Technology. Its product portfolio includes Intelligent Fingerprinting Platform that analyzes fingerprint sweat using a one-time cartridge and portable handheld reader, and a two-part system that consists of non-invasive, fingerprint sweat-based diagnostic testing products designed to detect drugs of abuse including opiates, cocaine, methamphetamines, benzodiazepines, cannabis, methadone, and buprenorphine. The Biosensor Platform is designed to detect multiple biological analytes by substituting the top enzyme layer of the biosensor to suit each analyte and to develop a range of Point of Care Tests, including the modalities of clinical chemistry, immunology, tumor markers, allergens, and endocrinology.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
